Metabolic syndrome (MetS) is associated with increased risk of cardiovascular disease. A new study published online in the Nournal of the International Neuropsychological Society shows that MetS also plays a role in cognitive performance.
A 35 year-old man with a history of hypertension, obstructive sleep apnea and obesity presents to clinic with complaints of non-cardiac chest discomfort. He is requesting refills of his blood pressure medications. His insurance changed 6 months ago and he has not had them since. The nurse performs the intake vital signs and reports that the patient has a blood pressure of 280/150 mmHg.
Patients who have hypertension may be at increased risk for cognitive decline and dementia. According to a study published in the October 2014 issue of JAMA Neurology, researchers have been trying to elucidate the timing and mechanism by which elevated blood pressure robs patients’ thinking abilities.
Proper blood pressure monitoring is a matter of life and death for patients diagnosed with hypertension. For many patients, treatment cost and complex testing regimens can make proper adherence a challenge.
Deaths from heart disease are dropping, but deaths related to hypertension and arrhythmias are on the rise, according to a new government study. The study was published in the Nov. 19 issue of the Journal of the American Medical Association, a cardiovascular disease theme issue. Findings were released early to coincide with presentation at the annual meeting of the American Heart Association, held from Nov. 15 to 19 in Chicago.
The most common cause of sudden cardiac death in young people is hypertrophic cardiomyopathy, an inherited condition that can lead to heart failure, angina, arrhythmia and sudden cardiac death. There is no medical treatment shown to halt or reverse the progression of the disease—just palliative care or surgery.